Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case.
Drug Discov Today
; 18(19-20): 1014-24, 2013 Oct.
Article
em En
| MEDLINE
| ID: mdl-23127858
ABSTRACT
In this study, the screening collections of two major pharmaceutical companies (AstraZeneca and Bayer Pharma AG) have been compared using a 2D molecular fingerprint by a nearest neighborhood approach. Results revealed a low overlap between both collections in terms of compound identity and similarity. This emphasizes the value of screening multiple compound collections to expand the chemical space that can be accessed by high-throughput screening (HTS).
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Indústria Farmacêutica
/
Bibliotecas de Moléculas Pequenas
/
Descoberta de Drogas
/
Ensaios de Triagem em Larga Escala
Tipo de estudo:
Diagnostic_studies
/
Screening_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Drug Discov Today
Assunto da revista:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Ano de publicação:
2013
Tipo de documento:
Article